Twist Bioscience Reports Strong Q2 2026 Performance with Sequential Revenue Growth

Twist Bioscience Corporation reported its 13th consecutive quarter of sequential revenue growth, driven by strong performance in DNA synthesis and therapeutics. The company raised fiscal 2026 revenue guidance to $442 million to $447 million and remains on track for adjusted EBITDA breakeven by Q4.

By Moby Intelligence May 4, 2026 3 min read · Yahoo Finance · May 4, 2026, 16:45 UTC

Tickers: $TWST

Topics: biotech dna_synthesis ngs_growth operational_leverage therapeutics

Read the full article at Yahoo Finance

More World news

Linnworks Survey Reveals US E-commerce Businesses Limit AI Role to Operational Support Over Financial Control PR Newswire · November 12, 2026, 13:43 UTC
DocsInk Rebrands as TraceWell Health and Launches Integrated Care Platform PR Newswire · November 12, 2026, 13:44 UTC
Zoom Ventures Invests in Medaica to Advance AI-Powered Virtual Healthcare Seeking Alpha · November 12, 2026, 13:40 UTC
Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC